{"preliminary_commentary":{"by_channel":{"x_thread":24,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03498521\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CUPISCO","nct_id":"NCT03498521","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cupisco-nct03498521. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CUPISCO","arms":[{"description":"Participants will be assigned to molecularly-guided therapy based on genomic profile.","label":"Molecularly-Guided Therapy","type":"EXPERIMENTAL"},{"description":"Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).","label":"Platinum-Based Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Foundation Medicine"],"completion_date":{"date":"2024-11-07","type":"ACTUAL"},"conditions":["Cancer of Unknown Primary Site"],"enrollment":{"count":529,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Alectinib","otherNames":[],"type":"DRUG"},{"name":"Vismodegib","otherNames":[],"type":"DRUG"},{"name":"Ipatasertib","otherNames":[],"type":"DRUG"},{"name":"Olaparib","otherNames":[],"type":"DRUG"},{"name":"Erlotinib","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Vemurafenib","otherNames":[],"type":"DRUG"},{"name":"Cobimetinib","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab Subcutaneous (SC)","otherNames":[],"type":"DRUG"},{"name":"Pertuzumab","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Entrectinib","otherNames":[],"type":"DRUG"},{"name":"Ivosidenib","otherNames":[],"type":"DRUG"},{"name":"Pemigatinib","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-19","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-02-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, until 330 PFS events were observed (approx. 4.3 years for MGT Cat 1 and 3.4 years for Chemotherapy Cat 1)."}],"references":[{"citation":"Kramer A, Bochtler T, Pauli C, Shiu KK, Cook N, Janoski de Menezes J, Pazo-Cid RA, Losa F, Robbrecht DGJ, Tomasek J, Arslan C, Ozguroglu M, Arni P, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Duran-Pacheco G, Ma N, Scarato J, Ross JS, Moch H, Mileshkin L. Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study. J Clin Oncol. 2026 Sep 3:JCO2502974. doi: 10.1200/JCO-25-02974. Online ahead of print.","pmid":"42691436","type":"DERIVED"},{"citation":"Kramer A, Bochtler T, Pauli C, Shiu KK, Cook N, de Menezes JJ, Pazo-Cid RA, Losa F, Robbrecht DG, Tomasek J, Arslan C, Ozguroglu M, Stahl M, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Duran-Pacheco G, Michaud C, Scarato J, Thomas M, Ross JS, Moch H, Mileshkin L. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31.","pmid":"39096924","type":"DERIVED"}],"start_date":{"date":"2018-07-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","url":"https://clinicaltrials.gov/study/NCT03498521"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cupisco-nct03498521"}